19.Mizushima Y, Hoshi K, Shoji Y.IgE rheumatoid factor in a case of rheumatoid arthritis with pleuritis. J Rheumatol 8,299-302,1980.

20.Mizushima Y, Hamano T, Yokoyama K.Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann Rheum Dis 41, 263-267, 1982.

21.Mizushima Y.Basic and clinical studies of prodrug and non-steroidal anti-inflammatory drugs. Pharmacol 25(Suppl),39-45,1982.

22.Mizushima Y, Yanagawa A, Hoshi K.Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol 35,666 -667,1983.

23.Mizushima Y, Kaneko K, Hoshi K.Targeting steroid therapy in rheumatoid arthritis. Ann Rheum Dis 42,479-780,1983.

24.Mizushima Y, Hoshi K, Aihara H, Kurachi M.Inhibition of bronchoconstriction by aerosol of a lipid emulsion containing prostaglandin E1. J Pharm Pharmacol 35,397,1983.

25.Mizushima Y, Wada Y, Etoh Y, Watanabe K.Antiinflammatory effects of indomethacin ester incorporated in lipid microsphere. J Pharm Pharmacol 35,398-399,1983.

26.Mizushima Y, Shoji Y, Hoshi K, Kiyokawa S.Detection and clinical significance of IgE rheumatod factor. J Rheumatol 11,22-26,1984.

27.Mizushima Y, Igarashi R, Hoshi K, Muramatsu M, Fujita A.Increase in incorporation into lymphocytes in vitro of esterified anti-inflammatory corticosteroids. Agents Actions 19,123-126,1986.

28.Mizushima Y.Chemotaxis and phagocytosis of leukocytes in Behcet's disease; an overview. In: Recent Advances in Behcet'sDisease. Royal Society of Medicine Services, London, 61-65,1986.
29.Shoji Y, Mizushima Y, Yanagawa A , Shiba T, Takei H, Fujii M, Amino M. Enhancement of anti-inflammatory effects of biphenylylacetic acid by its incorporation into lipid microspheres. J Pharm Pharmaocol 38,118-121,1986.

30.Yanagawa A, Mizushima Y, Komatsu A, Horiuchi M, Shirasawa E, Igarashi R.Application of a drug delivery system to a steroidal ophthalmic preparation with lipid microspheres. J Microencapsulation 4,329-331,1987.

31.Mizushima Y, Igarashi R, Hoshi K, Sim AK, Cleland ME, Hayashi H, Goto J.Marked enhancement in antithrombotic activity of isocarbacyclin following its incorporation into lipid microspehres. Prostaglandins 33,161-168,1987.

32.Mizushima Y, Shiokawa Y, Homma M, Kashiwazaki S, Ichikawa Y, Hashimoto H, Sakuma A.A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders. J Rheumatol 14,97-101,1987.

33.Mizushima Y, Matsuda T, Hoshi K, Ohno S.Induction of Behcet's disease symptoms following dental treatment and streptococcal antigen skin test. J Rheumatol 15,1029-1030,1988.

34. Mizushima Y.Clinical advantages of new drug delivery system in arthritis − an overview of current trends. J Am Med Assoc SEA (Suppl) 5,13-17,1989.

35.Hamza M, Mizushima Y.Behcet'sdisease and dental treatment. J Rheumatol 16:1612 -1613,1989.

36. International Study Group for Behcet's Disease: Wechsler B, Davatchi F, Mizushima Y et al. Criteria for diagnosis of Behcet's disease. Lancet 335:1078-1080,1989


Copyright 2004 Mizushima. All right reserved.